Darovasertib NDA under RTOR in a disease with one approved drug — approval creates the commercial foundation; rejection resets the entire uveal melanoma franchise

Bull

A positive RTOR outcome resulting in FDA approval of darovasertib/crizotinib would establish IDEAYA's first approved product in a disease with only one prior approved therapy (tebentafusp, restricted to HLA-A*02:01-positive patients), immediately opening a commercially addressable HLA-A2-negative population with no approved standard of care. Simultaneously, strong updated ORR, PFS, and OS data from the ~85 HLA-A2-positive patients at ESMO would validate the combination across the broader uveal melanoma population and support label expansion negotiations, meaningfully enlarging the commercial opportunity.

Bear

The most likely failure mode is an FDA Complete Response Letter citing insufficient evidence of clinical benefit from the single-arm OptimUM-01 dataset — regulators may demand a randomized controlled trial to confirm the ORR and PFS signals before granting approval, particularly given the absence of an established chemotherapy benchmark in this population. A second failure mode is a safety or manufacturing deficiency identified during RTOR review that delays or derails the NDA, resetting the commercial timeline and pressuring the stock given the capital recently raised on the expectation of an approval catalyst.